In a study published in Journal of Allergy and Clinical Immunology, Osaka University in Japan found that they studied the activity of signaling proteins. Signal proteins were found to be involved in allergic reactions and nasal polyps in patients with eosinophilic granulocytes (ECRS).
In ECRS, inflammation leads to the development of nasal polyps containing eosinophils, including sinus surgery and systemic glucocorticoids, but these treatments are sometimes not good and can have multiple side effects. Molecularly targeted therapy can provide new treatments for Patients with ECRS without these disadvantages. Because signalproteins have been found in inflamed airway tissue, it is an effective option for ECRS therapy.
The team at Osaka University found that activated eosinophils express high levels of signaling proteins on the surface of cells that can be released into their surroundings through enzyme reactions. This soluble signaling protein allows eosinophils to pass through endothelial cells, leading to inflammation and nasal polyps.
Takeshi Tsuda, lead author of the study, said: “Our analysis showed that in mice without signaling proteins in mice without signaling proteins, there was less inflammation in the nasal cavity than in normal mice, so we tested whether blocking signaling proteins with antibodies affected inflammation in normal mice with ECRS.” “
Based on the results of mouse models, the researchers found that blocking signaling proteins could provide a new treatment option for Patients with ECRS. In addition, an increase in the level of signaling protein in patients with ECRS indicates that the signaling protein is also a biomarker in ECRS patients.